Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001950047-25-003381
Filing Date
2025-05-23
Accepted
2025-05-23 16:04:26
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3315
  Complete submission text file 0001950047-25-003381.txt   4740
Mailing Address C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Business Address
Katkin Keith (Reporting) CIK: 0001314596 (see all company filings)

Type: 144

Mailing Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879
Business Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Subject) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-33137 | Film No.: 25982071
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)